Skip to content

LOVAFARMA

Active
Private limited companyfounded 2002active for 24 yearsDiestsesteenweg 133a, 3010 Leuven, BelgiumKBO/BCE: BE 0476.540.511
Summary

LOVAFARMA has been active since 2002 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €903,035 and a net result of €411,577. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 69% of 22,195 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€1.6mtotal assets 2025
Equity
€903,035
Profit
€411,577
Turnover not published (abbreviated or micro format)
Financial health
88 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.4%
Structure
Parent
DELCLE · 100%
Accounts filed 34 days late0 of 5 deeds read
Why 88raises risk1 change of registered office in 24 monthsLatest accounts 34 days late; 2 of the last 3 latelowers riskSize: total assets €1.6mLiquidity: current ratio 1.77, cash €261,639Show the evidence

Checked score

Score 2025
88 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 83% of its sector peers (NACE 47, micro)
Financial strength · tick = 2024
Strong
Solvency 81-13
equity 56.3% of total assets
Liquidity 69-1
short-term debt 12.8% · cash 16.3%
Profitability 100+7
return on assets 25.7%
Bankruptcy probability, 12 months
0.4% Very low
0%0.5%1.5%4%10%≥ 25%

About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,188 companies, NACE 47, micro)
Last 24 months 11-2024: 0.3% 12-2024: 0.3%● unchanged vs 11-2024 01-2025: 0.3%● unchanged vs 12-2024 02-2025: 0.8%▲ +0.5 percentage points vs 01-2025 03-2025: 0.8%● unchanged vs 02-2025 04-2025: 0.8%● unchanged vs 03-2025 05-2025: 0.8%● unchanged vs 04-2025 06-2025: 0.8%● unchanged vs 05-2025 07-2025: 0.8%● unchanged vs 06-2025 08-2025: 1.2%▲ +0.4 percentage points vs 07-2025highest value 09-2025: 0.2%▼ -1.0 percentage point vs 08-2025 10-2025: 0.2%● unchanged vs 09-2025 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025lowest value 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.2%● unchanged vs 02-2026 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.3%▲ +0.1 percentage points vs 04-2026 06-2026: 0.3%● unchanged vs 05-2026 07-2026: 0.3%● unchanged vs 06-2026 08-2026: 0.5%▲ +0.2 percentage points vs 07-2026 09-2026: 0.7%▲ +0.2 percentage points vs 08-2026 10-2026: 0.4%▼ -0.3 percentage points vs 09-2026
Credit of up to €75,000 on 30-day terms is acceptable
Liquidity ample (current ratio 1.77, compared with 2.38 in 2024; short-term debt: 12.8% and cash: 16.3% of total assets), and 43.7% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 70% on solvency, 75% on liquidity, 96% on profitability and 91% on growth.

The bankruptcy probability was computed on 09-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
−lowers risk+raises risk○neutral
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
raises risk · Latest accounts 34 days late; 2 of the last 3 late
NBB · filings
lowers risk · Size: total assets €1.6m
The company's size counts in the probability; how much depends on the rest of its profile.
NBB · annual accounts
lowers risk · Liquidity: current ratio 1.77, cash €261,639
NBB · annual accounts
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year €903,035
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-09-2026, 34 days later. For context: 47% of Belgian companies file late, and of those that file 1 to 90 days late, 2.0% are now in a legal situation other than normal in the KBO (such as bankruptcy, liquidation or dissolution), against 1.66% of all filers. We show this as a fact and do not score it.
NBB · 10 filings
Deviation from the deadline
2025
34 days late
2024
8 days late
2023
60 days late
2022
22 days late
2021
59 days early
2020
30 days early
2019
25 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 9 days after the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 22 August (4 of the last 5 filed years within 39 days of that day).
Companies Code · seven months
Where today falls in the filing period
09-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · micro…
  2. Highest result from 2018 to 2025net €411,577 ▲200%
  3. Equity above €500,000equity €903,035 ▲83.7%

Key points

  • Positive: Result rose in 2025from €137,154 to €411,577 ▲ 200% View
  • Positive: Among the best 5% on net resultsector median €5,027 · 22,174 companies €411,577 View
  • Positive: 8 profitable years in a rowprofit 2025: €411,577 8 years View
  • Controlled by DELCLE 100% View

By topic

Financials

Financial year
2025
Total assets
€1.6m
Profit
€411,577
Solvency
56.3%
Total assets▲ 124%
Net result
20182025
Go to Financials

Timeline

Events
29
Since
2003
Next accounts
by 31-07-2027
  1. 08-08-2025Annual accounts filed
  2. 31-12-2024Equity above €200,000
  3. 29-09-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
23-01-2002
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.